Ernexa Therapeutics Announces New Data to be Presented at AACR Annual Meeting 2025

Core Insights - Ernexa Therapeutics is presenting new data on its lead cell therapy product, ERNA-101, at the AACR Annual Meeting 2025, focusing on advanced cancer and autoimmune disease treatment [1][2] Company Overview - Ernexa Therapeutics specializes in innovative cell therapies targeting advanced solid tumors and autoimmune diseases, utilizing engineered induced pluripotent stem cells (iPSCs) to create allogeneic synthetic induced mesenchymal stem cells (iMSCs) [4] - The company is developing two main cell therapy products: ERNA-101 for ovarian cancer and ERNA-102 for autoimmune diseases, both currently in preclinical stages [5] Product Details - ERNA-101 employs specially engineered cells to deliver treatment directly to ovarian tumors by secreting immune-stimulating cytokines, aiming to enhance anti-tumor immune responses [2][5] - The study on ERNA-101 is led by Dr. Michael Andreeff from The University of Texas MD Anderson Cancer Center, highlighting its potential to reshape the tumor microenvironment [2] Presentation Information - The poster presentation for the study will take place on April 28, 2025, from 2:00–5:00 pm CDT, under the session category of Immunology, with details available for conference attendees [3]